DK3139963T3 - Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme - Google Patents

Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme Download PDF

Info

Publication number
DK3139963T3
DK3139963T3 DK15709742.9T DK15709742T DK3139963T3 DK 3139963 T3 DK3139963 T3 DK 3139963T3 DK 15709742 T DK15709742 T DK 15709742T DK 3139963 T3 DK3139963 T3 DK 3139963T3
Authority
DK
Denmark
Prior art keywords
prodrugs
conjugates
cancer
treatment
inflammatory diseases
Prior art date
Application number
DK15709742.9T
Other languages
Danish (da)
English (en)
Inventor
Sébastien Papot
Isabelle Opalinski
Brigitte Renoux
Thibaut Legigan
Original Assignee
Centre Nat Rech Scient
Univ Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Poitiers filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK3139963T3 publication Critical patent/DK3139963T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK15709742.9T 2014-02-07 2015-02-06 Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme DK3139963T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1450956A FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
PCT/IB2015/050914 WO2015118497A1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Publications (1)

Publication Number Publication Date
DK3139963T3 true DK3139963T3 (da) 2020-10-26

Family

ID=50829100

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15709742.9T DK3139963T3 (da) 2014-02-07 2015-02-06 Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme

Country Status (9)

Country Link
US (1) US10293021B2 (enExample)
EP (2) EP3139963B1 (enExample)
JP (1) JP6721512B2 (enExample)
CN (2) CN106573071A (enExample)
CA (1) CA2938501C (enExample)
DK (1) DK3139963T3 (enExample)
ES (1) ES2843798T3 (enExample)
FR (1) FR3017298B1 (enExample)
WO (1) WO2015118497A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722593B2 (en) 2015-10-02 2020-07-28 Sirenas Llc Anti-cancer compounds and conjugates thereof
CN108779146B (zh) * 2016-03-29 2022-03-18 东丽株式会社 肽衍生物及其用途
US11666657B2 (en) 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
AU2018375787B2 (en) * 2017-11-30 2023-02-23 Ladrx Corporation Albumin-binding prodrugs of auristatin E derivatives
CN120078904A (zh) * 2018-04-03 2025-06-03 辛迪维亚公司 细胞毒性药物的结合物和所述结合物的前体药物形式
JP7620569B2 (ja) * 2019-05-06 2025-01-23 セーキョー がん治療のための新規治療用ベクター及びプロドラッグ
FR3126982B1 (fr) * 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CN116077674B (zh) * 2022-12-26 2025-03-25 北京大学 生物分子-聚氮氧化物偶联物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PT3248613T (pt) * 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
FR2960153B1 (fr) * 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant

Also Published As

Publication number Publication date
ES2843798T3 (es) 2021-07-20
CN106573071A (zh) 2017-04-19
CN114917358A (zh) 2022-08-19
EP3766510A1 (fr) 2021-01-20
US10293021B2 (en) 2019-05-21
CA2938501A1 (fr) 2015-08-13
FR3017298A1 (fr) 2015-08-14
JP2017506628A (ja) 2017-03-09
EP3139963B1 (fr) 2020-10-07
JP6721512B2 (ja) 2020-07-15
CA2938501C (fr) 2022-04-05
US20170095525A1 (en) 2017-04-06
FR3017298B1 (fr) 2016-03-04
WO2015118497A1 (fr) 2015-08-13
EP3139963A1 (fr) 2017-03-15

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL255261A0 (en) Methods for treating cancer
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
HUE049072T2 (hu) AXL-specifikus ellenanyag-drog konjugátumok rák kezelésére
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
HUE059694T2 (hu) Készítmény rák kezelésére
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
HRP20181525T1 (hr) Postupak pročišćavanja konjugata cys-vezanih konjugata protutijelo-lijek
EP3474854A4 (en) DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER
DK3139963T3 (da) Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme
DK3622953T3 (da) Kombinationsbehandling af cancer
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
IL268463A (en) Cancer treatment
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3400072T3 (da) Formuleringer til behandling af blærecancer
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
EP3546020C0 (en) CANCER TREATMENT DEVICE
EP3413927A4 (en) CANCER THERAPY